Thrivent Financial for Lutherans’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$431M Buy
468,846
+3,836
+0.8% +$3.89M 0.82% 13
2025
Q4
$500M Buy
465,010
+9,296
+2% +$8.89M 0.89% 13
2025
Q3
$348M Buy
455,714
+5,787
+1% +$4.31M 0.68% 15
2025
Q2
$351M Buy
449,927
+52,783
+13% +$41M 0.77% 12
2025
Q1
$328M Sell
397,144
-71,592
-15% -$59.6M 0.72% 13
2024
Q4
$363M Buy
468,736
+40,776
+10% +$33.8M 0.7% 10
2024
Q3
$379M Buy
427,960
+62,378
+17% +$56.1M 0.72% 8
2024
Q2
$331M Buy
365,582
+133,475
+58% +$107M 0.67% 12
2024
Q1
$181M Buy
232,107
+124,984
+117% +$88.9M 0.36% 50
2023
Q4
$62.4M Sell
107,123
-6,956
-6% -$4.06M 0.14% 216
2023
Q3
$61.3M Sell
114,079
-5,878
-5% -$3.03M 0.15% 195
2023
Q2
$56.2M Buy
119,957
+40,963
+52% +$17.2M 0.13% 216
2023
Q1
$27.1M Buy
78,994
+775
+1% +$261K 0.07% 350
2022
Q4
$28.6M Sell
78,219
-9,048
-10% -$3.21M 0.07% 330
2022
Q3
$28.3M Sell
87,267
-3,504
-4% -$1.11M 0.08% 307
2022
Q2
$29.4M Sell
90,771
-58,515
-39% -$17.6M 0.08% 301
2022
Q1
$42.1M Sell
149,286
-6,637
-4% -$1.71M 0.08% 281
2021
Q4
$39.2M Sell
155,923
-41,257
-21% -$10.5M 0.08% 299
2021
Q3
$45.5M Sell
197,180
-119
-0.1% -$29.4K 0.09% 259
2021
Q2
$45.3M Sell
197,299
-4,587
-2% -$921K 0.09% 265
2021
Q1
$37.7M Sell
201,886
-52,716
-21% -$10.3M 0.08% 288
2020
Q4
$43M Sell
254,602
-60,326
-19% -$9.01M 0.1% 264
2020
Q3
$46.6M Buy
314,928
+87,658
+39% +$13.6M 0.12% 198
2020
Q2
$35.4M Buy
227,270
+87,077
+62% +$13.4M 0.11% 233
2020
Q1
$19.4M Buy
140,193
+54,401
+63% +$7.47M 0.07% 322
2019
Q4
$11.3M Sell
85,792
-1,675
-2% -$194K 0.03% 537
2019
Q3
$9.78M Buy
87,467
+443
+0.5% +$49.3K 0.03% 509
2019
Q2
$9.64M Sell
87,024
-61,755
-42% -$7.27M 0.03% 528
2019
Q1
$19.3M Sell
148,779
-194,494
-57% -$23.7M 0.06% 330
2018
Q4
$39.5M Buy
343,273
+7,929
+2% +$886K 0.14% 176
2018
Q3
$36M Sell
335,344
-10,058
-3% -$1.01M 0.11% 198
2018
Q2
$29.5M Sell
345,402
-1,192
-0.3% -$97.9K 0.1% 214
2018
Q1
$26.8M Buy
346,594
+206,748
+148% +$16.6M 0.09% 210
2017
Q4
$11.8M Buy
139,846
+47,461
+51% +$4.04M 0.04% 422
2017
Q3
$7.9M Buy
92,385
+53,315
+136% +$4.37M 0.03% 497
2017
Q2
$3.21M Buy
39,070
+1,654
+4% +$135K 0.01% 698
2017
Q1
$3.14M Buy
37,416
+2,850
+8% +$228K 0.01% 706
2016
Q4
$2.54M Buy
34,566
+1,790
+5% +$133K 0.01% 782
2016
Q3
$2.63M Buy
32,776
+1,820
+6% +$146K 0.01% 783
2016
Q2
$2.44M Buy
30,956
+1,556
+5% +$117K 0.01% 805
2016
Q1
$2.12M Buy
29,400
+1,470
+5% +$111K 0.01% 848
2015
Q4
$2.35M Buy
27,930
+1,280
+5% +$106K 0.01% 798
2015
Q3
$2.23M Buy
26,650
+550
+2% +$46.4K 0.01% 765
2015
Q2
$2.18M Sell
26,100
-19,881
-43% -$1.51M 0.01% 644
2015
Q1
$3.34M Buy
45,981
+800
+2% +$57K 0.02% 574
2014
Q4
$3.12M Sell
45,181
-800
-2% -$54K 0.02% 587
2014
Q3
$2.98M Buy
45,981
+2,300
+5% +$146K 0.02% 606
2014
Q2
$2.72M Buy
43,681
+450
+1% +$26.8K 0.02% 638
2014
Q1
$2.54M Buy
43,231
+1,950
+5% +$109K 0.02% 543
2013
Q4
$2.11M Sell
41,281
-1,816,270
-98% -$91M 0.01% 593
2013
Q3
$93.5M Buy
1,857,551
+11,681
+0.6% +$612K 0.59% 45
2013
Q2
$90.7K Buy
+1,845,870
New +$100M 0.59% 41

Other funds holding LLY

Thrivent Financial for Lutherans's LLY Position: Q1 2026 in Review

Thrivent Financial for Lutherans increased its Eli Lilly (LLY) stake by 0.82% in Q1 2026, buying an estimated $3.89M and bringing the position to 468,846 shares worth $431M. The position accounts for 0.82% of the portfolio, ranked #13.

Thrivent Financial for Lutherans first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $500M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Thrivent Financial for Lutherans held 468,846 shares of Eli Lilly worth $431M as of Q1 2026.
  • Thrivent Financial for Lutherans bought 3,836 Eli Lilly shares in Q1 2026, an estimated $3.89M.
  • Eli Lilly made up 0.82% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #13 holding.
  • Thrivent Financial for Lutherans first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Thrivent Financial for Lutherans's Eli Lilly position peaked at $500M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.